We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Vasoactive Peptides in Portal Pressure

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Bayside Health.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00163982
First Posted: September 14, 2005
Last Update Posted: July 26, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bayside Health
  Purpose
This study is looking at the detection of vasoactive peptides in portal hypertension.

Condition Intervention
Portal Hypertension Drug: Norfloxacin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment

Further study details as provided by Bayside Health:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • HVPG >= 12 mmHg
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00163982


Contacts
Contact: William W Kemp, MBBS, FRACP 92762000 ext 3327 w.kemp@alfred.org.au

Locations
Australia, Victoria
Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3181
Contact: William W Kemp, MBBS, FRACP    92762000 ext 3327    w.kemp@alfred.org.au   
Sponsors and Collaborators
Bayside Health
Investigators
Principal Investigator: William W Kemp, MBBS, FRACP The Alfred
  More Information

ClinicalTrials.gov Identifier: NCT00163982     History of Changes
Other Study ID Numbers: AH4204
First Submitted: September 13, 2005
First Posted: September 14, 2005
Last Update Posted: July 26, 2007
Last Verified: September 2005

Keywords provided by Bayside Health:
HVPG > 12 mmHg

Additional relevant MeSH terms:
Hypertension, Portal
Liver Diseases
Digestive System Diseases
Norfloxacin
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors